1,2,3,4-テトラクロロジベンゾ[1,4]ジオキシン

This chemical does not meet GHS hazard criteria for 7.1% (3 of 42) of reports.

Warning

H400 (92.9%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

SYMPTOMS: Ingestion, inhalation and skin contact to this class of compounds has caused chloracne which is characterized by comedones, keratin cysts, pustules, papules and abscesses. This may clear in a few months or persist for up to 15 years. Symptoms may occur weeks or months after initial exposure. Exposure to a related compound has caused endocrine, immunologic, hematologic, gastrointestinal and neuropsychiatric effects. Other symptoms include a burning sensation in the eyes, nose and throat; headache, dizziness, nausea, vomiting, arthralgias, extreme fatigue, insomnia, loss of libido, irritability, nervousness, high levels of cholesterol, hyperlipoproteinaemia, porphyria cutanea tarda, hepatic dysfunction, hyperpigmentation, hirsuitism, disorders of the cardiovascular, urinary, respiratory and pancreatic systems; disorders of fat and carbohydrate metabolism, emotional disorders, difficulties with muscular and mental coordination, blurred vision and loss of taste and smell. Itching, swelling and redness of the face may occur just prior to the appearance of chloracne. Other symptoms include muscular weakness, loss of appetite and weight, sleep disturbances, orthostatic hypotension, abdominal pain and liver impairment. It may also cause liver and kidney damage and personality changes.

CDDs are absorbed through oral, inhalation, and dermal routes of exposure. CDDs are carried in the plasma by serum lipids and lipoproteins, distributing mainly to the liver and adipose tissue. CDDs are very slowly metabolized by the microsomal monooxygenase system to polar metabolites that can undergo conjugation with glucuronic acid and glutathione. They may increase the rate of their own metabolism by inducing both phase I and phase II enzymes. The major routes of excretion of CDDs are the bile and the faeces, though smaller amounts are excreted in the urine and via lactation. (L177)

Dioxins occur as by-products from the manufacture of organochlorides, the bleaching of paper, chlorination by waste and drinking water treatment plants, municipal solid waste and industrial incinerators, and natural sources such as volcanoes and forest fires. (L177, L178)